Antigen binding proteins to oncostatin m (osm)

Abstract

The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

1 . A method of treating an inflammatory bowel disease in a subject comprising administering an effective amount of an antibody which specifically binds to human OSM (hOSM) wherein the antibody further comprises:
 i) CDRH2 of SEQ ID NO. 2;   ii) CDRH3 of SEQ ID NO. 3;   iii) CDRL1 of SEQ ID NO. 4; and   iv) CDRL3 of SEQ ID NO. 6   
     
     
         2 . The method of  claim 1  wherein the antibody further comprises:
 i) CDRH1 of SEQ ID NO. 77; 
 ii) CDRH2 of SEQ ID NO. 2; 
 iii) CDRH3 of SEQ ID NO. 3; 
 iv) CDRL1 of SEQ ID NO. 4; 
 v) CDRL2 of SEQ ID NO. 5; and 
 vi) CDRL3 of SEQ ID NO. 6. 
 
     
     
         3 . The method of  claim 2  wherein the antibody further comprising a heavy chain variable region of SEQ ID NO: 74 and a light chain variable region of SEQ ID NO: 62. 
     
     
         4 . The method of  claim 3  wherein the antibody further comprising a heavy chain amino acid sequence of SEQ ID NO: 76 and a light chain amino acid sequence of SEQ ID NO: 72. 
     
     
         5 . The method of  claim 1  wherein the antibody is encoded by a heavy chain variable region encoded by SEQ. ID. NO:73 and a light chain variable region encoded by SEQ. ID. NO:61 
     
     
         6 . The method of  claim 1  wherein the antibody is a humanised antibody. 
     
     
         7 . The method of  claim 1  wherein the antibody is IgG1. 
     
     
         8 . The method of  claim 1  wherein the antibody is administered with a pharmaceutically acceptable carrier. 
     
     
         9 . The method of  claim 1  wherein the treatment is prophylaxis. 
     
     
         10 . The method of  claim 1  wherein the inflammatory bowel disease is ulcerative colitis. 
     
     
         11 . The method of  claim 1  wherein the inflammatory bowel disease is Crohn's disease. 
     
     
         12 . A method of treating chronic inflammation and/or inflammatory bowel disease (IBD) in an individual, the method comprising:
 administering to the individual an antagonist of oncostatin-M (OSM), wherein the antagonist is an anti-OSM antibody or a polynucleic acid encoding an anti-OSM antibody.